Pandorum is a biotechnology company based out of the US and India, working in the field of Tissue Engineering and Regenerative Medicine. With its distinct synergy of life science, engineering and clinical competences, at Pandorum, we have developed a proprietary technology platform which combines therapeutic exosomes with anti-inflammatory, anti-fibrotic properties derived from clinical grade human stem cells and biomaterials with tissue-mimetic properties – to promote efficient regeneration of human tissues, such as cornea, liver and lung. Pandorum has been supported by a number of Govt. grants (BIG, SBIRI) and awards, and have raised funding from marquee investors and VCs. We are proud to have a world-class team of scientists, engineers, clinicians, and key opinion leaders deeply engaged in the product development and clinical translation. Pandorum's efforts towards clinical translation of its products have been supported by renowned medical Institutions such as, are Northwestern Medicine (Chicago, US), Medical University of South Carolina (Charleston, US) and Dr. Shroff’s Charity Eye Hospital (New Delhi, India). Pandorum is also proud to be an Endless Frontier Labs (EFL) start-up, NYU Stern School of Business, Life Sciences Cohort -2023. At Pandorum our efforts are dedicated to make Regenerative Medicine an efficacious and scalable mainstream reality, to be able to address the sufferings of millions across the globe affected by various diseases of unmet clinical needs